Skip to main content
SpringerLink
Log in

Adverse effects of high-dose interferon-α-2a treatment for chronic hepatitis B

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

The aim of this study was to assess morbidity and the incidence of adverse effects during interferon (IFN)-α-2a treatment of patients with chronic hepatitis B. This prospective study included 48 consecutive patients with chronic hepatitis B who underwent IFN-α-2a treatment from January 2003 to August 2005. Adverse effects related to IFN treatment were recorded during this period and for 6 mo after treatment. Adverse effects that led to dose reduction or early discontinuation of IFN treatment were examined. Complete response was reported in 25% of patients. At least 1 adverse effect was documented in 88% of patients. Flu-like symptoms were the most frequently observed adverse effects (88%), and thrombocytopenia (63%), leukopenia (54%), and anemia (23%) were also reported. Bleeding occurred in 2 patients. Other adverse effects included neuropsychiatric signs (21%), alopecia (19%), weight loss (17%), thyroid disorders (19%), menstrual cycle irregularities (8%), skin lesions (8%), and dry cough (4%). Adverse effects that led to dose reduction or early discontinuation of IFN treatment occurred in 19% of patients and included impotence, depression, seizure, thyroid disorders, severe thrombocytopenia, and intestinal bleeding. These effects were found to be unrelated to treatment response. No relationship was detected between patient age, duration of treatment, and adverse effects of IFN. Although IFN-α-2a treatment induced various adverse effects in patients with chronic hepatitis B, most of these effects were reversible or could be ameliorated. Adverse effects that led to dose reduction or early discontinuation of IFN treatment were found to be unrelated to complete response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.Liver Int. 2005;25:472–489.

    Article  PubMed  Google Scholar 

  2. Buti M, Esteban R. Drugs in development for hepatitis B.Drugs. 2005;65:1451–1460.

    Article  PubMed  CAS  Google Scholar 

  3. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C.Hepatology. 2001;34:395–403.

    Article  PubMed  CAS  Google Scholar 

  4. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin treatment in chronic hepatitis C-relapsed and treatment-naive patients.Semin Liver Dis. 1999;19:67–75.

    PubMed  CAS  Google Scholar 

  5. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C.Hepatology. 1997;26:112–121.

    Article  Google Scholar 

  6. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of side events in 11241 patients with chronic viral hepatitis treated with alfa interferon.J Hepatol. 1996;24:38–47.

    Article  PubMed  CAS  Google Scholar 

  7. Wai CT, Lok SF. Treatment of hepatitis B.J Gastroenterol. 2002;37:771–778.

    Article  PubMed  CAS  Google Scholar 

  8. Kraus MR, Schafer A, Csef H, Scheurlen M. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.World J Gastroenterol. 2005;11:1762–1774.

    Google Scholar 

  9. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral treatment for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.Cleveland Clin J Med. 2004;71:17–21.

    Article  Google Scholar 

  10. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a.Lur J Endocrinol. 1995; 132:587–593.

    Article  CAS  Google Scholar 

  11. Fried MW. Side effects of treatment of hepatitis C and their management.Hepatology. 2002; 36:237–244.

    Article  Google Scholar 

  12. Cadoni G, Marinelli L, De Santis A, Romito A, Mana R, Ottavianni F. Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha-interferon: a possible autoimmune-microvascular pathogenesis.J Laryngol Otol. 1998;112:962–963.

    Article  PubMed  CAS  Google Scholar 

  13. Karim A, Ahmed S, Khan A, Steinberg H, Mattana J. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection.Am J Med Sci. 2001;22:233–235.

    Article  Google Scholar 

  14. Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Side effects of interferon on the cardiovascular system in patients with chronic hepatitis C.Jpn Heart J. 1996;37:905–915.

    PubMed  CAS  Google Scholar 

  15. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high dose interferon treatment for chronic hepatitis C.J Hepatol. 1996;25:283–291.

    Article  PubMed  CAS  Google Scholar 

  16. Dormann H, Krebs S, Muth-Selbach U, et al. Rapid onset of hematotoxic effects after interferon alpha in hepatitis C.J Hepatol. 2000;32:1041–1042.

    Article  PubMed  CAS  Google Scholar 

  17. Renou C, Harafa A, Bouabdallah R, et al. Severe neutropenia and post-hepatitis C cirrhosis treatment: is Interferon dose adaptation at once necessary?Am J Gastroenterol. 2002;97:1260–1262.

    Article  PubMed  CAS  Google Scholar 

  18. Prummel MF, Laurberg P. Interferon-α and autoimmune thyroid disease.Thyroid. 2003;13:547–551.

    Article  PubMed  CAS  Google Scholar 

  19. Fontaine H, Pol S. Side effect of interferon-α in treating hepatitis C virus infection.Transplant Proc. 2001;33:2327–2329.

    Article  PubMed  CAS  Google Scholar 

  20. Wong V, Xi-Li Fu A, George J, Cheung NW. Thyrotoxicosis induced by alpha-interferon treatment in chronic viral hepatitis.Clin Endocrinol. 2002;56:793–798.

    Article  CAS  Google Scholar 

  21. Kakizaki S, Takagi H, Murakami M, Takayama H, Mori M. HLA antigens in patients with interferon-α-induced autoimmune thyroid disorders in chronic hepatitis C.J Hepatol. 1999;30:794–800.

    Article  PubMed  CAS  Google Scholar 

  22. Gupta G, Holmes SC, Spence E, Mills P. Capillaritis associated with interferon-alfa treatment of chronic hepatitis C infection.J Am Acad Dermatol.2000;43:937–938.

    Article  PubMed  CAS  Google Scholar 

  23. Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-α.Br J Dermatol. 1991;125:463–465.

    Article  PubMed  CAS  Google Scholar 

  24. Kelkar PS, Kalaaji AN. Urticarial vasculitis with asymptomatic chronic hepatitis infection: response to doxepin, interferon-alfa, and ribavirin.J Clin Gastroenterol. 2002;35:281–282.

    Article  PubMed  Google Scholar 

  25. Aspinall RJ, Pockros PJ. The management of side-effects during treatment for hepatitis C.Aliment Pharmacol Ther. 2004;20:917–929.

    Article  PubMed  CAS  Google Scholar 

  26. Gutierrez G, Pereda A. Granulocyte colony stimulating factor for the treatment of interferoninduced neutropenia in patients with chronic hepatitis B.J Pediatr Gastroenterol Nutr. 2001; 32:225.

    PubMed  CAS  Google Scholar 

  27. Talal AH, Weisz K, Hau T, Kreiswirth S, Dieterich DT. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-α.Am J Gastroenterol. 2001;96:2802–2803.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases and Clinical Bacteriology, Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey

    Elif Doyuk Kartal, Saygin Nayman Alpat, Ilhan Ozgunes & Gaye Usluer

Authors
  1. Elif Doyuk Kartal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saygin Nayman Alpat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ilhan Ozgunes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gaye Usluer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elif Doyuk Kartal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kartal, E.D., Alpat, S.N., Ozgunes, I. et al. Adverse effects of high-dose interferon-α-2a treatment for chronic hepatitis B. Adv Therapy 24, 963–971 (2007). https://doi.org/10.1007/BF02877700

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02877700

Keywords

Search

Navigation